In view of the importance to use multiple cell lines, HT29 (HER3/MET‐high CRC) was selected for the in vitro and in vivo evaluation of dual‐targeting therapy against HER3 and MET. The gene discussed is ERBB3; the disease is colorectal carcinoma.